FDA approves Bausch Lomb & Modulight’s ML6710i photodynamic laser

Bausch + Lomb and Modulight announced that the U.S. Food and Drug Administration FDA has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE or verteporfin for injection photodynamic therapy,PDT, for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration ,AMD, 1 ML6710i is expected to be available for eye care professionals during the first half of 2023. "PDT continues to be an important treatment option for eye care professionals who are looking to treat patients with predominantly classic subfoveal choroidal neovascularization," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb